GSK - GlaxoSmithKline PLC
This page shows which of the focused investors we track hold GSK and how their positions changed, so you can see how much conviction the group has in the stock.
In Q4 2017 it was held by 6 managers with an aggregate reported value of $1.7B, which is 0.19% of the combined portfolio.
As of Q4 2017, 6 tracked institutional managers held GSK (GlaxoSmithKline PLC) with an aggregate reported value of $1.7B — 0.19% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades GSK — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q4 2017
- Ticker
- GSK
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Dodge & Cox - Dodge & Cox | 1.21% | Add +196.7% | 44,083,293 | $1.56B |
| 2 | Ariel Investments - Ariel Investments | 0.71% | Add +5.6% | 1,779,641 | $63.12M |
| 3 | Kahn Brothers Group - Kahn Brothers Group | 6.35% | Add +11.6% | 1,139,163 | $40.41M |
| 4 | Sarah Ketterer - Causeway Capital Management | 0.24% | Add +14.4% | 630,163 | $22.35M |
| 5 | Tweedy Browne Co. - Tweedy Browne Value Fund | 0.19% | Add +80.7% | 197,274 | $7M |
| 6 | First Eagle - First Eagle Investment Management | 0.00% | - | 1 | $0 |
Loading holder history for GSK…